רדאר קליני AI | ||
|---|---|---|
הניסוי הקליני NCT07047612 עבור Non Segmental Vitiligo הוא מגייס. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן. | ||
ICP-332 in Subjects With Non-segmental Vitiligo שלב II, שלב III 603 אקראי סמיות כפולה מבוקר פלסבו תכנון מסתגל
A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo
- ICP-CL-00607
שלב III
| קבוצת משתתפים/זרוע | התערבות/טיפול |
|---|---|
ניסיICP-332 dose A(Phase2) | ICP-332 Tablets ICP-332 will be administered as tablet |
פלצבו להשוואהPlacebo(Phase2) | ICP-332 Placebo Tablets ICP-332 Placebo will be administered as tablet |
ניסיICP-332 dose B(Phase2:) | ICP-332 Tablets ICP-332 will be administered as tablet |
ניסיICP-332 dose A or dose B(Phase3) | ICP-332 Tablets ICP-332 will be administered as tablet |
פלצבו להשוואהPlacebo(Phase3) | ICP-332 Placebo Tablets ICP-332 Placebo will be administered as tablet |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Phase2: Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24. | 24 weeks | |
Phase3: Proportion of subjects achieving F-VASI 75 at Week 52. | 52 weeks |
Male or female subjects aged ≥18 years and ≤75 years (Phase II portion). Male or female subjects ≥12 years of age and ≤75 years of age, adolescent subjects must weigh ≥40 kg (Phase III portion).
Eligible subjects must meet all of the following criteria at screening and baseline:
- The clinical diagnosis was non-segmental vitiligo for at least 3 months.
- Involvement of BSA≥5%.
- Facial involvement BSA≥0.5%.
- F-VASI≥0.5 and T-VASI between 5 and 50.
- Active or stable non-segmental vitiligo was present at both screening and baseline visits.
Women of childbearing potential (WOCBP) and Men must agree to contraception.
Before beginning any screening or study specific procedures, subjects must voluntarily sign informed consent.
Any of the following vitiligo related medical conditions and other skin diseases/conditions.
a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2.
History of any clinically major diseases, with the exception of vitiligo.
Pregnant or breastfeeding females.
The investigator considers that the subject is not suitable for participation in this study for any reason.
Anhui
Beijing Municipality
Chongqing Municipality
Fujian
Guangdong
Hebei
Henan
Hubei
Hunan
Jiangsu
Jiangxi
Jilin
Liaoning
Shandong
Shanghai Municipality
Shanxi
Sichuan
Yunnan
Zhejiang